Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SG301 in kidney transplant recipients with antibody-mediated rejection
CTR20262229Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SG301 in humoral rejection, sponsored by Shangjian Bio. Started Jun 2026; status: active.
02
Drugs
SG301
03
Conditions
humoral rejection
Beyond the preview
Go deeper on CTR20262229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262229.